A new method to measure cancer cell metabolism without damaging samples
Non-destructive optical spectroscopic assay for high-throughput metabolic characterization of in vitro cell models and patient-derived organoids
This study is looking at a new way to see how cancer cells, especially in breast cancer, react to treatments by using special light techniques, which could help doctors find better ways to treat patients over time.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10823336 on NIH RePORTER |
What this research studies
This research focuses on developing a non-destructive optical spectroscopic assay to measure the metabolism of cancer cells and patient-derived organoids. By using advanced fluorescence techniques and machine learning algorithms, the study aims to provide real-time insights into how tumors respond to therapies, particularly in breast cancer. This approach allows for repeated measurements on the same samples, which is crucial for understanding tumor behavior over time. Patients may benefit from improved treatment strategies based on these metabolic insights.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer who are undergoing or considering radiotherapy.
Not a fit: Patients with non-breast cancer types or those not undergoing any form of therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment plans for breast cancer patients.
How similar studies have performed: Previous research has shown promise in using non-invasive techniques for metabolic measurements, indicating potential success for this novel approach.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Zhu, Caigang — University of Kentucky
- Study coordinator: Zhu, Caigang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.